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Abstract In two separate previous studies, we reported
that subcutaneous (sc) or oral administration of (-)–epi-
gallocatechin-3-gallate (EGCG) limited the development
of muscle degeneration of mdx mice, a mild phenotype
model for Duchenne muscular dystrophy (DMD). How-
ever, it was not possible to conclude which was the more
efﬁcient route of EGCG administration because different
strains of mdx mice, periods of treatment and methods of
assessment were used. In this study, we investigated which
administration routes and dosages of EGCG are the most
effective for limiting the onset of dystrophic lesions in the
same strain of mdx mice and applying the same methods of
assessment. Three-week-old mdx mice were injected sc
for 5 weeks with either saline or a daily average of 3 or
6 mg/kg EGCG. For comparison, age-matched mdx mice
were fed for 5 weeks with either a diet containing 0.1%
EGCG or a control diet. The effects of EGCG were assessed
quantitatively by determining the activities of serum
muscle-derived creatine kinase, isometric contractions of
triceps surae muscles, integrated spontaneous locomotor
activities, and oxidative stress and ﬁbrosis in selected
muscles. Oral administration of 180 mg/kg/day EGCG in
the diet was found the most effective for signiﬁcantly
improving several parameters associated with muscular
dystrophy. However, the improvements were slightly less
than those observed previously for sc injection started
immediately after birth. The efﬁcacy of EGCG for limiting
the development of dystrophic muscle lesions in mice
suggests that EGCG may be of beneﬁt for DMD patients.
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Introduction
Duchenne muscular dystrophy (DMD) is an X-linked
progressive muscle-wasting disease. Its primary defect is
mutations and deletions in the dystrophin gene, resulting in
a lack of dystrophin at the inner face of the sarcolemma. In
normal cells, dystrophin connects the cytoskeletal F-actins
to the extracellular matrix through a dystrophin-associated
glycoprotein complex in the sarcolemma (Davies and No-
wak 2006) and stabilizes the sarcolemma during muscle
contractions (Petrof et al. 1993). The absence of dystrophin
causes not only mechanical damage in the sarcolemma but
also abnormal regulation of reactive oxygen species (ROS),
cell signaling and ion channels, followed by elevated
calcium inﬂux into myoﬁbres and calcium-dependent pro-
teolysis of myoﬁbrils, and other dysfunctions such as
inﬂammation and apoptosis (Allen et al. 2010; Evans et al.
2009a, b; Tidball and Wehling-Henricks 2007; Whitehead
et al. 2006, 2010). This leads to repeated cycles of muscle
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wasting and ﬁbrosis. Currently, the molecular mechanism
underlying the pathogenesis of DMD is not fully elucidated
and there is no established therapy available.
Increased oxidative stress is a major contributing factor
in the pathology of DMD and in dystrophin-deﬁcient
muscles in an animal model of DMD, the mdx mouse
(Rando 2002; Tidball and Wehling-Henricks 2007;
Whitehead et al. 2006). For the past decade, several groups,
including ours, have investigated the antioxidant effects of
a green tea polyphenol mixture (GTP) and its major active
constituent (-)-epigallocatechin-3-gallate (EGCG), in mdx
mice. The main ﬁndings reported to date are as follows:
1. Mdx mice fed with a diet containing 0.01 or 0.05%
GTP for 4 weeks from birth (through their dams before
weaning) diminishes necrosis in their extensor digito-
rum longus (EDL) muscles (Buetler et al. 2002).
2. Feeding 3-week-old mdx mice with a diet containing
0.05 or 0.25% GTP or 0.1% EGCG for 1 or 5 weeks
increases their antioxidant potential in plasma, reduces
necrosis in their EDL muscles, and improves isometric
contraction parameters of their triceps surae muscles
(Dorchies et al. 2006).
3. Subcutaneous (sc) injection of 5 mg/kg EGCG four
times a week from birth for 8 weeks limits the onset of
muscular dystrophy in mdx mice by protecting the
sarcolemma from damage as judged by their near
normal levels of muscle-derived creatine kinase (CK)
in sera, a reduction in the amount of intra- and
intermyoﬁbre lipofuscin (LF) or ceroid (Porta 2002),
less ﬁbrosis and fewer necrotic myoﬁbres, more
histologically normal myoﬁbres, and enhanced expres-
sion of utrophin, a homologue of dystrophin (Nakae
et al. 2008).
4. Diet containing 0.5% GTP given to mdx mice from
gestation to 6 weeks after birth increases their volun-
tary wheel running activities, citrate synthase activities
in gastrocnemius muscle, lowers lipid peroxidation in
cardiac and gastrocnemius muscles, and decreases
sarcolemmal damage (Call et al. 2008). This last
EGCG treatment also improves the histopathology of
mdx tibialis anterior muscles and down-regulates
activated NF-jB in the nuclei of the regenerating
myoﬁbres (Evans et al. 2010).
The beneﬁcial effects of GTP, and more especially
EGCG, on dystrophin-deﬁcient muscles seem to be related
to their high antioxidant activity (Higdon and Frei 2003),
low molecular weight (458 Da for EGCG), and low tox-
icity (Chan et al. 2010; Goodin and Rosengren 2003;
Isbrucker et al. 2006a, b; McCormick et al. 1999). A major
source of ROS in dystrophic mdx muscles has been
attributed to NADPH oxidase (NOX), expression of which
is enhanced in dystrophic muscles (Shkryl et al. 2009;
Whitehead et al. 2010). The ROS produced by this enzyme
regulate many fundamental physiological events in the cell
(Brown and Griendling 2009), but excessive ROS pro-
duction causes cellular dysfunctions, such as an increase in
stretch-induced Ca
2? inﬂux into mdx myoﬁbres resulting in
force reduction (Whitehead et al. 2010). EGCG, epicate-
chin, and its methylated metabolite also inhibit ROS
production by NOX in non-muscle cells (Morre ´ et al. 2000;
Nishikawa et al. 2007; Steffen et al. 2007, 2008). More-
over, EGCG interacts with plasma membrane 67-kDa
laminin receptor (67LR; Tachibana et al. 2004), which is
up-regulated in mdx muscle cells (Dorchies et al. 2009).
One aim of the present study was to investigate whether
sc EGCG administration to mdx mice starting 3 weeks after
birth, when muscle degeneration had already begun
(Coulton et al. 1988; Dangain and Vrbova 1984; Louboutin
et al. 1993; Passaquin et al. 2002), was as effective for
limiting the onset of dystrophic lesions as EGCG admin-
istration begun the day after birth. In addition, the efﬁcacy
of different routes and doses of EGCG administration were
investigated quantitatively using several assessment crite-
ria. One criterion we used was accumulated oxidative stress
in selective muscles, which was determined as the amount
of intramuscular LF granules that are formed. LF is an
autoﬂuorescent end-product of lipid peroxidation and is
widely accepted as an index of chronic oxidative stress
(Brunk and Terman 2002; Sohal and Brunk 1989; Terman
and Brunk 1998).
We found that EGCG administered either sc or orally to
mdx mice beginning at 3 weeks after birth leads to similar
improvements to those observed previously for sc injection
started immediately after birth (Nakae et al. 2008). Of the
treatment protocols investigated, oral administration of
180 mg/kg EGCG daily in the diet for 5 weeks was found
to be the most effective for reducing muscular dystrophy.
Materials and methods
Animals
Dystrophic C57BL/10-mdx (mdx) mice obtained from
Charles River France (Iffa Credo, Lyon) and wild-type
(WT) C57BL/10 mice from Charles River Deutschland
(Sulzfeld, Germany) and the Jackson Laboratory (Bar
Harbor, ME, USA) were used. They were fed with standard
laboratory rodent diet pellets, given free access to water,
and housed in a room with 12 h light/dark cycles at
20 ± 1C. Males and females of the same strain were
mated and the pregnant females housed in cages lined with
soft bedding material (small cotton pads and ﬁne wood
chips). For the EGCG experiments, only male littermate
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123neonates were used. They were divided into test and con-
trol groups at 3-weeks-old. All experiments were carried
out according to the guidelines based on the Swiss Federal
Law on Animal Welfare of the Swiss Federal Veterinary
Ofﬁce and were approved by the Cantonal Veterinary
Service.
EGCG administration
(-)-Epigallocatechin-3-gallate (Sunphenon brand EGCG,
lot 503310; purity [90%, caffeine \1%), extracted
from green tea, was kindly donated by Taiyo Kagaku
(Yokkaichi, Japan). For sc administration, it was dissolved
in sterile physiological saline (0.9% NaCl) at a concen-
tration of 0.3 or 0.6%. The EGCG solutions were ﬁltered
through a sterile syringe 0.20-lm pore ﬁlter (DISMIC-
13cp; Advantec Toyo, Tokyo, Japan), stored at 4C, and
used within 10 days after preparation. Calculated volumes
of the EGCG solution corresponding to a dose of 5 or
10 mg EGCG/kg body weight (bw) were injected sc using
autoclaved microsyringes (Hamilton, Reno, Nevada, USA)
into the backs of mdx mice four times a week for 5 weeks
beginning when they were 3-weeks-old. The lower and
higher doses of the sc administrations are equivalent to
average daily dosages of 3 and 6 mg/kg, respectively
(Tables 1, 2). As controls, mdx and WT mice were injected
with physiological saline only. At the end of a treatment
schedule, all assessments, except for locomotor activity,
were carried out 24–48 h after the ﬁnal sc injection as we
found during the course of this study that handling of mdx
mice for injection increases their serum creatine kinase
activities. The activities do not reach constant low base
levels until at least 24 h after the injection.
For oral administration of EGCG, mdx mice were fed for
5 weeks, beginning when they were 3-weeks-old, with
standard rodent diet pellets containing 0.1% EGCG pre-
pared by Provimi Kliba (Kaiseraugst, Switzerland). Mdx
and WT mice fed with standard diet were used as oral
administration controls. Body weights and chow con-
sumption of mdx mice were measured weekly. The daily
average diet consumption (g) per gram bw was calculated
from the food consumed at the end of each week.
Serum creatine kinase (CK) assays
Blood sampling for CK assays was carried out bysaphenous
vein puncture (Hem et al. 1998). The left lateral ankle was
shaved and the lateral saphenous vein pricked with a sterile
needle (25 G 9 16 mm). The drop of blood (about 20 ll)
was collected with a pipette ﬁtted with a sterile tip. The
procedurewascompletedwithin3–4 minafterﬁrsthandling
a mouse. The blood samples were kept at room temperature
for 30 min and then centrifuged at 1,0009g at 4C for
20 min to obtain sera. The sera were stored at 4C and used
within 3 days for CK assays. The serum CK activities were
measured as the initial velocities of NADPH formation at
37C over 10 min in a microplate reader (Fluostar Optima;
BMG Labtech Sarl, Champigny-sur-Marne, France) using a
commercial CK assay kit (Catachem, Bridgeport, CT, USA)
according to the manufacturer’s instructions. Catatrol I
(Catachem) was used as a positive control. The activities
were expressed as U/l.
Spontaneous locomotor activity
At the end of a treatment schedule, spontaneous locomotor
activities of test and control mice were measured simul-
taneously in separate transparent-plastic cages using a
LOCOMO sensor system consisting of LOCOMO sensor
units (LS-5), a counter interface (CIF-mini4), a control unit
(LCU-20) and a personal computer with WinCIF II mini
software (Melquest, Toyama, Japan). The counter interface
counted the interruptions of latticed infrared-beams by a
mouse moving in the cage inside the sensor. The locomotor
activity was expressed as the counts integrated for 12 h
from 19.00 h to 7.00 h in the dark phase. The relative
locomotor activity of a test mdx mouse was expressed as
the ratio of its activity to that of a control mouse measured
simultaneously to minimize the effects of circumstances
and condition of the mouse on the activity.
Isometric force measurements
Animals were anaesthetized by intraperitoneal injection of a
mixture of urethane (1.5 g/kg bw) and diazepam (5 mg/kg
bw) in saline. The Achilles tendon of the right hind limb
was exposed and linked to a force transducer coupled to a
LabView interface for trace acquisition and analysis. The
knee joint was ﬁrmly immobilized. Two thin steel elec-
trodes were inserted into the triceps surae muscle. The
muscles were electrically stimulated with 0.5-ms square
pulses of controlled intensity and frequency. The stimula-
tion-recording protocol and data analyses were performed
as described previously (Dorchies et al. 2006; Reutenauer
et al. 2008; Hibaoui et al. 2011). Absolute phasic and tetanic
tensions were converted into speciﬁc tensions (mN per mm
2
of muscle section) after normalization for the muscle cross-
sectional area (CSA). The CSA values (mm
2) were deter-
mined by dividing the triceps surae muscle mass in mg, by
the product of the optimal length Lo in mm and d, the
density of mammalian skeletal muscle (1.06 mg/mm
3).
Preparation of tissue sections
After completion of the force measurements, blood was
collected from the heart (see below). The left costal part of
Histochem Cell Biol (2012) 137:811–827 813
123the diaphragm muscle, the left extensor digitorum longus
(EDL) muscle, liver and right kidney were excised,
immediately placed in PolyFreeze (Polysciences, War-
rington, PA, USA) and quenched in isopentane cooled by
liquid nitrogen. Transverse sections, 7-lm-thick, were cut
at -20C at the mid-belly of the EDL muscles and in the
middle region (corresponding to mid-belly) of the dia-
phragm muscles in a cryostat (Cryo-Star HM 560 M;
MICROM International, Walldorf, Germany), dried at
room temperature and kept at -80C until used for his-
tology or histochemistry. Seven-lm-thick sections of liver
and kidney were prepared similarly.
Oxidative stress
The levels of accumulated oxidative stress in individual
muscles were estimated by counting the numbers of auto-
ﬂuorescent LF granules they contained as described pre-
viously (Nakae et al. 2001, 2004, 2008) in sections of
diaphragm and EDL muscles mounted in a mixture of
13.3% Mowiol 4-88 Reagent (CalBiochem, San Diego,
CA, USA) and 33.3% glycerol (Fluka, Buchs, Switzerland)
in 0.133 M Tris–HCl buffer, pH 8.5. In preliminary
experiments, we found that the relative sectional area
occupied by the granules, whose Feret diameters were
mostly between 2 and 5 lm, correlated strongly with their
counts per unit area, thus validating this methodology.
One muscle section prepared as described in the previous
paragraph was used for the measurement in each muscle.
Emission signals at 515 nm from the section excited at
450–490 nm were captured as 50–60 or 10–15 images for
one whole section of diaphragm or EDL muscle, respec-
tively, using a Spot Insight B/W camera (model 3.1, Visi-
tron Systems, Puchheim, Germany), ﬁtted to a ﬂuorescence
light microscope with a 920 objective (Zeiss Axiovert
200 M; Carl Zeiss MicroImaging, Jena, Germany). The
total number of LF granules and tissue area were deter-
mined in every captured image using the ‘cell counter’
function and ‘measure area’ function, respectively, of
ImageJ free software version 1.41o (NIH, Maryland, USA).
Assuming that the muscle sections were uniformly 7-lm
thick, the number of LF granules per mm
3 of diaphragm or
EDL muscle was calculated for each mouse. Microphoto-
graphs of serial sections stained with Mayer’s haematoxylin
and eosin were taken with a Spot Insight QE camera (model
4.2; Visitron Systems) ﬁtted to the same light microscope.
MetaView software (Visitron Systems) was used for cap-
turing both colour and black and white images.
Fibrosis
To evaluate the ﬁbrosis in each muscle, the amount of
intermyoﬁbre connective tissue formed in selected muscles
was quantiﬁed in situ by utilizing the speciﬁc binding of
wheat-germ agglutinin (WGA) to N-acetylglucosamine and
sialic acid residues in proteoglycans, polysaccharides and
glycoproteins in the extracellular matrix (Dunn et al. 1982;
Kostrominova 2011). Transverse sections of diaphragm
and EDL muscles, prepared as described previously, were
labelled with 2 lg/ml WGA-Alexa Fluor 594 conjugate
(Molecular Probes, Eugene, OR, USA) in phosphate-buf-
fered saline (PBS), pH 7.4, at room temperature for 1 h
according to a modiﬁcation of the method described by
Briguet et al. (2004). The labelled sections were rinsed for
10 min in two changes of ice-cold PBS and then mounted
in the Mowiol mounting medium referred to earlier.
Emission signals at 615 nm from the labelled sections
excited at 530–585 nm were captured as 10–23 or 3–6
images for respectively one whole section of the left costal
part of diaphragm or left EDL muscle for each mouse using
a 910 objective as described in the previous paragraph.
Using the ImageJ version 1.41o software, the percentage of
WGA-labelled tissue area of the total tissue area in each
section of diaphragm or EDL muscle was determined in the
captured images converted to binary images by applying
the automatic threshold function of the software. However,
the connective tissue in the epimysium was excluded from
the quantiﬁcation as only the ﬁbrotic deposits in the
endomysium and perimysium are relevant for DMD path-
ogenesis. Serial sections were stained with Mayer’s hae-
matoxylin and eosin.
Plasma EGCG assays
Immediately after the force measurements of the triceps
surae muscle had been completed, the chest cavity was
exposed. 10 ll 5% heparin sodium salt (147 USP units/mg;
Sigma, St. Louis, MO, USA) in saline was injected into the
heart, and a blood sample for HPLC analysis taken by
cardiac puncture. The blood samples were kept at room
temperature for 30 min and then centrifuged at 1,0009g at
4C for 20 min to obtain the plasma. The plasma samples
were stabilised by adding 10 ll antioxidant mixture per
100 mg plasma. The antioxidant solution consisted of 20%
ascorbic acid and 0.1% EDTA in 0.4 M NaH2PO4–H3PO4
buffer, pH 3.6 (Lee et al. 2000). The samples were stored at
-80C until use.
The EGCG concentrations in the plasma samples were
determined according to the method of Zimmermann et al.
(2009). The samples were thawed and their sulphated and
glucuronidated EGCG content deconjugated by adding to
200 ll aliquots, 50 ll of an enzyme suspension containing
40 U sulphatase (type VIII, EC 232-772-1, puriﬁed from
abalone entrails; Sigma-Aldrich, Steinheim, Germany) and
500 U b-glucuronidase (type VII-A, EC 232-606-8, puri-
ﬁed from E. coli, Sigma-Aldrich) followed by incubation at
814 Histochem Cell Biol (2012) 137:811–827
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100 ll dimethylformamide and 20 ll 50% (w/w) aqueous
trichloroacetic acid to the treated plasma, and then sepa-
rated by centrifugation at 8,8009g for 7 min. Twenty llo f
the supernatant was injected into a HPLC. The total EGCG
content was identiﬁed and quantiﬁed by HPLC with elec-
trochemical detection as described in Zimmermann et al.
(2009). Unconjugated (free) EGCG was determined simi-
larly in parallel samples to which no enzyme suspension
had been added. The lowest limit of EGCG quantiﬁcation
was 5.0 ng/ml plasma, recovery 96.5%, and the coefﬁcient
of variation 8.6%.
Data analyses and recovery scores
Data were expressed as means ± SEM and analysed using
GraphPad Prism software version 5.0c (GraphPad Software,
La Jolla, CA, USA). A two-tailed paired Student’s t test (for
data on the relative locomotor activities in mdx mice in
Fig. 4b) or a two-tailed unpaired Student’s t test (for com-
parison in oral administration groups in Fig. 1 and com-
parison between mdx controls either with or without saline
injection and corresponding WT controls in Fig. 4a) was
used to assess statistical signiﬁcances between two means.
Whenever more than three groups of mdx and WT mice
treated by the same administration route had to be com-
pared, their data were subjected to one-way ANOVA fol-
lowed by Tukey’s multiple-comparison test to compare all
pairs of the groups. Differences were considered signiﬁcant
at P B 0.05. Signiﬁcance levels are denoted as follows:
***P\0.001; **0.001 B P B 0.01; *0.01\P B 0.05.
The mean differences ± SEM in the parameters
between test mdx mice or WT controls and corresponding
mdx controls treated by the same route were denoted by
Dt and Do, respectively, and expressed as percentage
(Table 2). Statistically signiﬁcant improvements of the
parameters after EGCG treatment were expressed as
recovery scores (%) calculated as (Dt/Do) 9 100 (Table 2)
as proposed by Gillis (2002).
The correlation of locomotor activity with LF formation
or ﬁbrosis in muscles was analysed using the same Prism
software.
Results
Effects of the EGCG treatments on mouse body weights
and food intake
Neither sc nor oral EGCG treatments for 5 weeks had any
signiﬁcant effects on the mean body weights of mdx mice
as compared to the corresponding controls (Fig. 1a). Sim-
ilarly, the mean daily food intake was unaffected by the
treatments (Fig. 1b). It was in the range 0.170–0.194 g/g
bw/day for the control diet mice and 0.173–0.194 g/g bw/
day for mice fed with the 0.1% EGCG diet. The daily
average EGCG intake by the dietary route was equivalent
to 180 mg/kg bw in mdx mice and was 20% higher than
that reported previously for mdx
5Cv mice, another mutant
strain (Dorchies et al. 2006).
Effects of handling and injection procedures on serum
creatine kinase (CK) levels
To obtain reliable data on the changes in CK levels in
individual mice during EGCG treatment, the effects of
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body weights (b)o fmdx mice during EGCG administration from age
3 to 8 weeks. a When compared with the corresponding control
group, there was no signiﬁcant difference in the mean body weights of
the sc injection groups (n = 9 for each group) and oral administration
groups (n = 8 or 10) throughout the treatment. b 0.1% EGCG in the
diet has no signiﬁcant effect on food intake by mdx mice (n = 8 for
control group and n = 10 for test group). The daily EGCG delivery
by the diet route averaged 180 mg/kg bw
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123handling mice, saline sc injection and the blood drawing
procedure on serum CK levels were ﬁrst examined. This
enabled the best time window for blood collection after a sc
injection to be determined. Just before the ﬁrst blood
sample was drawn from the lateral saphenous vein at time
zero, 9-week-old male mdx mice were divided into three
groups. The ﬁrst group was injected with physiological
saline (1.67 ml/kg) sc at the same dose used in the EGCG
treatment protocol. The second group was sham-injected
and the third group received no prior treatment. The time-
course of serum CK activity was measured in each mouse
over a 24–27.5 h period after the ﬁrst blood collection at
time zero. The mean CK activities of the three mdx groups
in blood samples withdrawn immediately, or shortly after,
a sc injection ranged from 7,400 to 14,000 U/l. They
increased 7- to 12-fold in samples withdrawn over the next
2 h, but then decreased exponentially and returned to the
original levels after 24 h (Fig. 2). Similar time courses of
CK activities were observed in the three groups of mdx
mice subjected to different injection procedures, suggesting
that the changes were due to the trauma caused by the ﬁrst
blood withdrawal. In contrast, age-matched male WT mice
without pre-treatment showed no such changes in their
serum CK activities after the ﬁrst blood sampling (Fig. 2).
Subsequently, all blood samples for CK assays in this study
were collected via the left lateral saphenous vein at least
24 h after a previous sc injection or blood sampling.
Serum CK activities monitored during EGCG
administration
Before EGCG treatment, the mean serum CK activities in
3-week-old mdx mice (11,300 ± 1,050 U/l, n = 34) were
about threefold higher than that of age-matched WT mice
(3,890 ± 880 U/l, n = 13). The time courses of the serum
CK levels during EGCG treatment are shown in Fig. 3
where the CK levels in mdx mice are expressed as the mean
activities relative to the mean CK activities of 3-week-old
mdx mice in each treatment group before EGCG treatment.
The CK levels in WT mice with or without saline injection
were expressed as the mean activities relative to the mean
CK activities of 3-week-old mdx mice before EGCG
treatment. The mean CK levels in untreated mdx and WT
mice decreased as they grew older. During the ﬁrst 3 weeks
of EGCG treatment, whether by the sc or oral route, the
mean CK levels in mdx mice fell similarly to their
respective controls. In contrast, the mean CK activity in
mdx mice given 5 mg/kg EGCG 4 times a week sc for
2 weeks longer was reduced signiﬁcantly by 57 ± 7%
(Fig. 3a; Tables 1, 2). The recovery score was 61%
(Table 2). The mean CK level in mdx mice given a higher
dose (10 mg/kg EGCG 4 times a week) by the same sc
injection protocol showed less reduction, 40 ± 14% at the
end of sc treatment period, compared to the saline-treated
control (Fig. 3a; Tables 1, 2). However, this reduction was
not statistically signiﬁcant. Feeding 3-week-old mdx mice
with 0.1% EGCG in their diet for 4 weeks reduced their
mean serum CK activity highly signiﬁcantly by 45 ± 8%
as compared to that of untreated mdx controls (Fig. 3b;
Tables 1, 2). The recovery score was 55% (Table 2). In
contrast, oral EGCG treatment of mdx mice for a week
longer resulted in a smaller and non-signiﬁcant reduction
(26 ± 12%) in the mean CK activities (Fig. 3b).
Effects of EGCG treatments on isometric contraction
parameters
Sc injection of 5 mg/kg EGCG for 5 weeks signiﬁcantly
increased the mean speciﬁc phasic twitch tension
(Pt = 59.9 ± 5.0 mN/mm
2) and speciﬁc maximum tetanic
tension (Po = 222 ± 17 mN/mm
2) of triceps surae muscles
of 8-week-old saline-injected mdx mice by 28 ± 5 and
29 ± 5%, respectively (Tables 1, 2). The recovery scores
for the Pt and Po were 27 and 28%, respectively (Table 2).
When compared with mdx mice given the control diet, oral
EGCG administration also increased Pt (65.4 ± 3.7 mN/
mm
2) and Po (234 ± 9 mN/mm
2) highly signiﬁcantly by
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12332 ± 4 and 37 ± 7%, respectively (Tables 1, 2). The
recovery scores for Pt and Po were 40 and 41%, respectively
(Table 2). In contrast, sc injection of 10 mg/kg EGCG did
not signiﬁcantly alter either Pt or Po (Tables 1, 2). Other
isometric force parameters of mdx triceps surae muscles,
such as the time to twitch peak and the time for half-
relaxation from the peak, were both signiﬁcantly lower
(P\0.001) than those of the corresponding WT muscles,
but neither oral or sc EGCG administration had any sig-
niﬁcant effect on these parameters (Tables 1, 2). The EGCG
treatments also did not signiﬁcantly alter tension–frequency
relationships, muscle resistance to repetitive tetanization
(an assay for evaluating fatigue) and phasic-to-tetanic ratios
in mdx triceps surae muscles (data not included here). The
mean cross-sectional area of the triceps surae muscles in
mdx mice was reduced signiﬁcantly by 12 ± 2% to almost
the normal level after oral EGCG treatment (Tables 1, 2)
but not by ECGC administered by sc routes.
Effects of the EGCG treatments on spontaneous
locomotor activities
Sc saline injection alone 4 times a week for 5 weeks had no
signiﬁcant effects on the mean integrated locomotor activity
of either 8-week-old mdx or WT mice (Fig. 4a). The mean
locomotor activity (2,060 ± 160 counts per 12 h dark
phase, n = 17) of mdx mice, with or without saline sc
injection, was signiﬁcantly 34 ± 5% lower than that
(3,120 ± 300 counts, n = 15) of the corresponding WT
mice (Fig. 4a). Sc injection of 5 mg/kg and 10 mg/kg
EGCG resulted in signiﬁcant and dose-dependent increases,
by 36 ± 16 and 55 ± 18%, respectively, in the relative
locomotor activities (compared to that of saline-injected
mdx mice measured simultaneously) (Fig. 4b; Tables 1, 2).
The recovery scores after treatments with the lower and
higher doses of EGCG were 62 and 95%, respectively
(Table 2). Feeding with 0.1% EGCG increased the loco-
motor activities of mdx mice less, by 13 ± 8%: this increase
was not statistically signiﬁcant (Fig. 4b; Tables 1, 2).
Effects of EGCG treatments on oxidative stress
in muscles
Figure 5 shows the effects of EGCG treatments on LF
formation in mdx diaphragm and EDL muscles. Autoﬂuo-
rescent LF granules were rarely seen in these muscles of
8-week-old WT mice (Fig. 5d, g, h; Table 1; Nakae et al.
2001, 2004). In contrast, as reported previously (Nakae
et al. 2001, 2004, 2008), very high numbers of LF granules
(60,300 ± 3,710/mm
3, n = 13) were observed focally in
myoﬁbres and interstitial cells in the regions with typical
features of muscle degeneration and regeneration in dia-
phragm muscles of age-matched mdx controls either with
or without saline sc injection (Fig. 5b, e, g; Table 1).
Table 2 Mean differences (%) ± SEM and signiﬁcances of the mean values of the muscle parameters reported in Table 1
Mouse: Mdx mice Wild-type controls
Administration route: Subcutaneous Oral Subcutaneous Oral
Average daily EGCG-intake: 3 mg/kg 6 mg/kg 180 mg/kg 0 mg/kg 0 mg/kg
Difference compared to:
Saline control Saline control Diet control Mdx saline Mdx diet
Serum CK activity -57 ± 7* (61) -40 ± 14 -45 ± 8** (55) -94 ± 2*** -82 ± 4***
Force parameters of triceps surae muscle
Speciﬁc phasic twitch tension (Pt) ?28 ± 5* (27) ?24 ± 4 ?32 ± 4*** (40) ?102 ± 7*** ?80 ± 6***
Speciﬁc maximum tetanic tension (Po) ?29 ± 5** (28) ?19 ± 5 ?37 ± 7** (41) ?105 ± 3*** ?91 ± 8***
Time to peak -1.4 ± 2.0 -3.6 ± 3.2 ?2.9 ± 1.3 ?52 ± 5*** ?41 ± 8***
Half relaxation time -7.8 ± 2.2 -2.6 ± 3.0 -9.0 ± 1.9 ?36 ± 7*** ?18 ± 7*
Cross-sectional area (CSA) -2.6 ± 2.6 -2.6 ± 2.2 -12 ± 2* (86) -10 ± 4 -14 ± 4**
Spontaneous locomotor activity ?36 ± 16* (62) ?55 ± 18* (95) ?13 ± 8 ?58 ± 25* ?46 ± 16*
Number of lipofuscin granules
Diaphragm muscle -0.7 ± 8.9 -22 ± 4 -29 ± 3*** (30) -98 ± 1*** -98 ± 1***
EDL muscle ?15 ± 12 ?37 ± 12 ?16 ± 8 -80 ± 2** -81 ± 3***
Fibrosis
Diaphragm muscle ?1.6 ± 2.3 -0.6 ± 3.7 -0.7 ± 2.1 - 27 ± 2*** -25 ± 2***
EDL muscle -5.8 ± 2.7 -8.0 ± 7.1 -12 ± 2* (48) -33 ± 4** -25 ± 4***
The recovery scores (%) calculated for the signiﬁcant differences are in parentheses
Signiﬁcances: *** P\0.001, ** 0.001 B P B 0.01, * 0.01\P B 0.05. Where no signiﬁcance is indicated, the difference was not signiﬁcant
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123Feeding with 0.1% EGCG in the diet for 5 weeks reduced
the mean number of LF granules by 29 ± 3% in mdx
diaphragm muscles (Fig. 5f, g; Tables 1, 2). The reduction
was highly signiﬁcant (P\0.001). The recovery score was
30% (Table 2). In contrast, although sc EGCG adminis-
tration, particularly at the higher dose tested, reduced LF
accumulation by 22 ± 4% in mdx diaphragm muscles, the
reduction was not signiﬁcant (Fig. 5 g: Tables 1, 2).
EDL muscles of mdx untreated controls and controls
saline-injected contained far fewer LF granules (8,580 ±
880/mm
3, n = 16) (Fig. 5 h; Table 1) compared to the
corresponding diaphragm muscles. Further, neither oral nor
sc administration of EGCG had any signiﬁcant effect on
the mean LF number in EDL muscles though any EGCG
treatment appears to increase the number slightly (Fig. 5 h;
Tables 1, 2).
The number of LF granules per unit area was found to
correlate strongly with the percentage area they occupied,
as also reported by Tohma et al. (2011), and thus is a reli-
able parameter for the amount of LF that is formed: a plot of
the areas for LF granules in mdx and WT muscles against
counts showed a linear relationship with a high correlation
coefﬁcient (R
2 = 0.924; Nakae et al. in preparation).
Effects of EGCG treatments on ﬁbrosis in muscles
As Fig. 6a–f illustrates, the main structure labelled with
WGA-Alexa Fluor 594 conjugate in sections of skeletal
muscle was the connective tissue surrounding either the
myoﬁbres (consisting of the endomysium and perimy-
sium) or the entire muscle (consisting of the epimysium).
Muscle spindles, nerve bundles and blood vessels present
in the connective tissue were also labelled as reported
previously (Dunn et al. 1982; Kostrominova 2011). In
addition to the connective tissue, cytoplasmic clumps in
regenerating myoﬁbres and centrally located nuclei of
immature and regenerated myoﬁbres were also labelled
by the WGA conjugate. The mean ± SEM of the relative
areas of labelled cytoplasmic clumps and central nuclei
to the total labelled areas accounted for as little as 2.88 ±
0.66% (n = 15) and thus was considered negligible.
The mean relative area of connective tissue in sections
of EDL muscles was about 30% signiﬁcantly higher in mdx
mice than that in WT mice (Fig. 6 g; Tables 1, 2). Oral but
not sc EGCG administration signiﬁcantly reduced the
ﬁbrosis of mdx EDL muscles by 12 ± 2% (Fig. 6e–g;
Tables 1, 2). The recovery score was 48% (Table 2). In
sharp contrast, none of the EGCG treatments had a sig-
niﬁcant effect on the ﬁbrosis of mdx diaphragm muscle
although the amount of connective tissue in this muscle
was about 25% signiﬁcantly higher compared to the WT
muscle (Fig. 6 h; Tables 1, 2).
Relationship of spontaneous locomotor activity
and oxidative stress or ﬁbrosis
The mean numbers of LF granules formed in mdx dia-
phragm or EDL muscle (y axis) correlated signiﬁcantly
with the corresponding mean relative locomotor activities
(x axis) in mdx mice sc injected with 10 mg/kg EGCG or
fed with 0.1% EGCG diet (Fig. 7b, c, e, f). The equations
of the correlation regression lines are indicated in the ﬁgure
legends. In contrast, there was no signiﬁcant correla-
tion between these variables in mdx mice sc injected with
5 mg/kg EGCG (Fig. 7a, d).
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Fig. 3 Mean relative CK activities in sera determined continuously
in the same mdx mice given EGCG a sc (n = 4–7 for each
experimental point) or b orally in the diet (n = 4–10 for each
experimental point). The serum CK levels at each age point of control
WT mice treated with saline (n = 7 or 8) or a control diet (n = 4–6)
were normalized by dividing the activities by the mean CK activities
in 3-week-old mdx mice (11,300 U/l) before EGCG treatment. When
compared with the activities in corresponding mdx controls, the mean
relative CK activities of mdx mice were reduced signiﬁcantly by
57 ± 7% (n = 7) after 5-week sc administration with the lower dose
of EGCG and by 45 ± 8% (n = 9) after 4-week oral administration
of EGCG. Signiﬁcance levels denoted as ***P\0.001;
**0.001 B PB 0.01; *0.01\P B 0.05 are for the comparison to
corresponding mdx controls
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123The relative areas of intermyoﬁbre connective tissue
(ﬁbrosis) in EDL muscles (y axis) plotted on the relative
locomotor activities (x axis) showed a signiﬁcant correla-
tion only for mdx mice given 0.1% dietary EGCG
(Fig. 7 g). The same plots for EDL and diaphragm muscles
in sc EGCG-injected mdx mice and those for diaphragm
muscles in mdx mice given EGCG sc or orally showed no
signiﬁcant correlations because the changes in ﬁbrosis by
the treatments were too small.
Plasma EGCG concentrations
The mean ± SEM concentrations of free and total EGCG
determined in plasma in mdx mice fed with 0.1% EGCG
diet for 5 weeks were 27.6 ± 3.2 ng/ml (n = 10) and
29.7 ± 3.9 ng/ml (n = 10), respectively. These values
were not signiﬁcantly different. The mean concentration of
conjugated EGCG was 2.08 ± 2.19 ng/ml (n = 10). For
EGCG administered by sc routes, the EGCG concentra-
tions in mdx plasma samples (n = 10) obtained 24–48 h
after at the end of a treatment schedule were below the
limit of quantiﬁcation by HPLC.
Effects of EGCG treatments on organ histology
At the light microscopical level, no histological changes
were observed in haematoxylin–eosin stained sections of
livers (n = 10) and kidneys (n = 10) of 8-week-old mdx
mice fed with 0.1% EGCG in their diet for 5 weeks.
Discussion
In this paper, we report that treatment of mdx mice,
beginning when they are 3-weeks-old, with EGCG, either
injected sc (3 mg or 6 mg/kg/day) or given orally in their
diet (180 mg/kg/day), delays or limits the development of
dystrophic lesions. The improvements in muscle function
and structure are similar to those observed previously for sc
injection (3 mg EGCG kg/day) started immediately after
birth (Nakae et al. 2008), although there were some dif-
ferences. The EGCG doses delivered in the present study
were not toxic: they had no effect on body weight (Fig. 1a),
food intake (Fig. 1b) or liver and kidney histology. The
absence of adverse effects agrees with our previous reports
(Dorchies et al. 2006; Nakae et al. 2008). In contrast, we
found that one-day-old mdx pups died within 24 h after a
single sc injection of 25 mg/kg EGCG (Nakae et al.,
unpublished data). Hepatonecrotic responses have been
reported when much higher EGCG doses were adminis-
tered, for example 50 mg EGCG kg/day injected intra-
peritoneally into adult mice for 7 days (Goodin and
Rosengren 2003). Therefore, sc doses of EGCG higher than
10 mg/kg were not used in our investigation to avoid their
adverse effects.
We were concerned that repeated handling and injec-
tions may affect serum CK levels of mdx mice. Conse-
quently, we ﬁrst determined the time course of CK
activities over 24 h after an initial blood withdrawal
(Fig. 2). We found that the initial handling of mdx mice,
but not WT mice, causes substantial increases in the serum
CK levels during the ﬁrst 1–2 h. This was followed by a
progressive return to the initial levels by 24 h. Therefore,
to avoid handling-mediated artefacts, blood samples for
CK assay were collected 24 h after a sc injection. Our
ﬁnding of variable rises in CK levels in mdx mice sub-
jected to mild trauma is consistent with previous reports
(e.g. Grounds et al. 2008).
By avoiding the stress-induced CK changes, we found
that the serum CK levels in untreated mdx and WT mice
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123decrease with age from 3 to 8 weeks (Fig. 3b), agreeing
with earlier ﬁndings (Coulton et al. 1988). The age
dependency of CK release mirrors the changes with age of
the relative area of degenerating myoﬁbres in mdx tibialis
anterior muscle (Evans et al. 2010), indicating that serum
CK activity is a marker that closely parallels sarcolemmal
damage followed by necrosis. Oral administration of
180 mg EGCG/kg/day or a sc injection protocol delivering
on average 3 mg EGCG/kg/day to young mdx mice for 4 or
5 weeks signiﬁcantly recovered serum CK levels towards
normal levels by 55–61% (Table 2). However, this
improvement was not as great as the 75% recovery to
normal levels observed previously in age-matched mdx
mice injected sc from birth with an average 3 mg EGCG/
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haematoxylin and eosin. d–f Autoﬂuorescent images of serial muscle
sections. Mdx control muscles show the typical muscle degeneration
and regeneration (b) and abundant LF granules (white dots in e), a
product of oxidative stress (g, h). LF granules are rarely seen in
muscles in age-matched WT mice (a, d, g, h). In diaphragm muscles
of mdx mice given 0.1% EGCG in their diet, the histology of the
muscles is more normal, and the mean number of LF granules is
signiﬁcantly 29 ± 3% (n = 10) less than in mdx controls (c, f, g). In
contrast, none of the EGCG treatments had a signiﬁcant effect on LF
formation in mdx EDL muscles (h). g n = 6–10 per group,
h n = 7–10 per group. ***P\0.001, **0.001 B P B 0.01
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123kg/day (Nakae et al. 2008). This suggests that the EGCG
treatment started prior to the onset of massive necrosis in
most mdx muscles, which occurs about 3–4 weeks after
birth (Coulton et al. 1988; Dangain and Vrbova 1984;
Louboutin et al. 1993; Passaquin et al. 2002), protects the
sarcolemma of mdx myoﬁbres effectively. This is
supported by previous evidence that mdx muscles are
subjected to free-radical mediated injury even during the
pre-necrotic state (Disatnik et al. 1998).
Sc injection of the lower dose of EGCG (but not the
higher dose) and oral administration of EGCG led to
recoveries of the deﬁcit in speciﬁc phasic twitch tensions
(Pt)o fmdx triceps surae muscles by 27 and 40%, respec-
tively, compared to normal muscles. Similarly, the deﬁcit
in speciﬁc tetanic tensions (Po) recovered by 28 and 41%,
respectively (Table 2). Oral administration of EGCG led to
the cross-sectional area (CSA) of mdx triceps surae muscle
being reduced by 12%, a recovery score of 86% (Tables 1, 2).
0
10
20
30
R
e
l
a
t
i
v
e
 
a
r
e
a
 
(
%
)
EGCG (mg/kg)
sc injection
EGCG (%)
in diet
NaCl (%)
sc injection
Mdx mice
*
***
**
g
*
*
EDL
0
10
20
30
40
EGCG (mg/kg)
sc injection
EGCG (%)
in diet
Mdx mice WT mice
0 5 10 0 0.1 0 0.9 0 5 10 0 0.1 0 0.9
NaCl (%)
sc injection
***
***
h
Diaphragm
R
e
l
a
t
i
v
e
 
a
r
e
a
 
(
%
)
WT mice
Fig. 6 Effects of EGCG on ﬁbrosis (connective tissue formation) in
EDL (b, c, e, f, g) and diaphragm (h) muscles of 8-week-old mdx
mice at the end of EGCG treatment schedules. a–c EDL muscle
sections stained with haematoxylin and eosin. d–f Connective tissue
labelled with WGA-Alexa Fluor 594 conjugate in serial muscle
sections. Signiﬁcantly more connective tissue is seen in the
perimysium and endomysium in mdx control muscles (b, e, g, h)
than in muscles in age-matched WT mice (a, d, g, h). Administration
of 0.1% dietary EGCG signiﬁcantly diminished the relative area of
ﬁbrosis by 12 ± 2% (n = 10) in mdx EDL muscle (c, f, g), but not in
mdx diaphragm muscle (h). g n = 7–10 per group, h n = 7–10 per
group. ***P\0.001, **0.001 B P B 0.01, *0.01\P B 0.05
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123This suggests that EGCG protects this muscle against
dystrophy-related hypertrophy (Sacco et al. 1992). The
40% recovery score of Pt after oral EGCG administration is
close to the 65% that Dorchies et al. (2006) reported pre-
viously. However, in their study, oral EGCG treatment did
not affect Po and the CSA of mdx
5Cv triceps surae muscle
although it improved other parameters, such as the time-to-
peak and time for half relaxation from the peak, to normal
levels. These differences may be due to the different strains
of mdx mice that were used (Willmann et al. 2009):
Dorchies et al. (2006) used both males and females from
the mdx
5Cv allelic variant, whereas only males from the
original mdx strain were used in the present study.
Recently, Beastrom et al. (2011) found that the mdx
5Cv
strain is more severely affected than the original mdx
strain. This may be due to the mdx
5Cv strain being unable to
produce either non-muscle dystrophin isoforms or shorter
forms of muscle-speciﬁc dystrophin that are found in the
so-called revertant myoﬁbres of the original mdx strain.
The spontaneous locomotor activities of mdx mice injec-
ted sc with EGCG increased signiﬁcantly by 36–55%
(Fig. 4b;Tables 1, 2). However, micefed EGCG intheir diet
showed only a small, non-signiﬁcant increase (13 ± 8%) in
locomotor activity (Fig. 4b; Tables 1, 2). This is in marked
contrast with the observation that administration of 0.1%
dietary EGCG to age-matched male mdx
5Cv mice fully
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Fig. 7 Relationship of spontaneous locomotor activity to LF forma-
tion (an index of oxidative stress a–f) or the relative area of
connective tissue (an index of ﬁbrosis g) in 8-week-old mdx mice at
the end of EGCG treatment schedules. a–c Diaphragm muscles,
d–g EDL muscles. The solid and dashed correlation regression lines
show signiﬁcant (P B 0.05) and non-signiﬁcant correlations, respec-
tively, between the two variables. The relationships are approximated
by: a y =- 24,800x ? 90,600 (R
2 = 0.455, P = 0.0667, n = 8),
b y =- 15,500x ? 69,100 (R
2 = 0.820, P = 0.0129, n = 6),
c y =- 22,300x ? 68,800 (R
2 = 0.502, P = 0.0327, n = 9),
d y =- 1,360x ? 12,300 (R
2 = 0.0245, P = 0.711, n = 8),
e y = 6,260x ? 2,680 (R
2 = 0.661, P = 0.0492, n = 6),
f y =- 9,620x ? 21,300 (R
2 = 0.717, P = 0.00200, n = 10), and
g y =- 5.23x ? 23.5 (R
2 = 0.554, P = 0.0136, n = 10). The neg-
ative slopes of the lines in b, c, and g suggest that increases in
locomotor activities by EGCG administration correlate signiﬁcantly
with decreases in oxidative stress in diaphragm muscles or ﬁbrosis in
EDL muscles. In contrast, the slope of the line for the correlation of
locomotor activity with oxidative stress in EDL muscle is positive
(e) or negative (f) depending on the routes and doses of EGCG
administration
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123normalized their spontaneous activities (Dorchies et al.,
unpublished data). As discussed above, the inconsistency of
these data may be due to variations in the phenotypes of the
C57BL/10-mdx and C57BL/6-mdx
5Cv strains with different
genetic backgrounds (Beastrom et al. 2011; Fukada et al.
2010; Willmann et al. 2009).
The higher sc EGCG dose was expected to be as
effective as the lower dose in improving muscle function,
but the substantially increased, near normal, locomotor
activities of the treated mice (Table 2) may compete with
the recovered stability of the sarcolemma and eventually
damage it. This may explain why the 10 mg/kg EGCG
dose did not lead to signiﬁcant or dose-dependent changes
in serum CK levels and muscle tensions (Fig. 3a; Table 2).
Similar observations have been reported by Call et al.
(2008), who found that young mdx mice given green tea
extract in their diet were much more active than untreated
mice in a spontaneous wheel-running assay, but showed no
signiﬁcant reduction in serum CK levels.
We found that oral EGCG administration signiﬁcantly
reduced the number of LF granules in mdx diaphragm
muscles by 29 ± 3% (Fig. 5 g; Tables 1, 2) and such a
reduction is consistent with the 40% increase in the mean
antioxidant potential of the plasma of mdx
5Cv mice given
EGCG in their diet (Dorchies et al. 2006). The low dose
EGCG injection schedule in the present study did not
reduce LF formation signiﬁcantly in diaphragm muscle, in
contrast to our previous report (Nakae et al. 2008) that
showed signiﬁcant reduction by 53 ± 4 and 41 ± 11% in
mdx diaphragm and soleus muscles, respectively, when the
same dose of EGCG was injected for 8 weeks from birth.
This suggests that EGCG treatment should be started as
early as possible in order to protect diaphragm muscle
efﬁciently from oxidative stress.
Fibrosis is about 25–30% higher in diaphragm and EDL
muscles of untreated 8-week-old mdx mice compared with
thatinage-matchednormalmice(Fig. 6 g,h;Tables 1,2).In
mdx mice, ﬁbrosis was greater in the diaphragm muscle than
in the EDL muscle (Fig. 6 g, h; Table 1) because the dia-
phragm muscle is more susceptible to work-induced injury
than other skeletal muscles (Stedman et al. 1991). Orally
administered EGCG signiﬁcantly reduced the amount of
connective tissue present in mdx EDL muscle by 12 ± 2%, a
recovery score of 48% (Fig. 6f, g; Tables 1, 2). In contrast,
ﬁbrosis in mdx diaphragm muscle was not signiﬁcantly
improved by any of the EGCG schedules we employed,
unlike as reported previously (Nakae et al. 2008), where
ﬁbrosis was reduced signiﬁcantly by 41 ± 5a n d2 0± 11%
in mdx diaphragm and soleus muscles, respectively, when sc
injection of EGCG was started from birth.
An interesting observation in treating mdx mice with
EGCG sc is increased spontaneous locomotor activity
(Fig. 4b; Tables 1, 2). We found that the EGCG-mediated
alterations of locomotor activity correlated inversely with
the numbers of LF granules in diaphragm muscles (Fig. 7b,
c) and with ﬁbrosis in EDL muscles (Fig. 7 g). One might
expect that the increased locomotor activity would increase
the oxidative stress in myoﬁbres, which would in turn lead
to the formation of more LF granules (Faist et al. 2001).
Because spontaneous locomotor activity is a relatively mild
exercise, we hypothesise that the oxidative stress caused by
it should be buffered by EGCG, either by acting as a free
radical scavenger or indirectly by interacting with high
afﬁnity targets (such as superoxide-producing NOX
enzyme and signalling molecules in the NF-jB pathway;
Khan and Mukhtar 2008; Morre ´ et al. 2000; Nishikawa
et al. 2007; Shimizu and Weinstein 2005; Steffen et al.
2007, 2008), or both. For EGCG to be effective as a radical
scavenger, it must be present at micromolar levels in tis-
sues, whereas its indirect effect can be achieved at much
lower tissue concentrations, typically in the range
0.1–1.0 lM (Shimizu and Weinstein 2005). However, the
current consensus of opinion is that the in vivo free-radical
scavenging activity of ﬂavonoids (which include EGCG) is
minor and their interactions with high afﬁnity targets may
be more important (Schewe et al. 2008).
The maximum concentration of EGCG in plasma in mice
after a single EGCG dose of 10 kg/mg intravenously or
180 mg/kg intragastrically is respectively 2.73 lM( L a m b e r t
et al. 2006)o r0 . 6 8 1lM (calculated from data in Lambert
et al. 2006). When EGCG is injected sc, its maximum con-
centration in plasma is probably lower than 2.73 lM but it is
retained in mice longer than EGCG administered intrave-
nously or intragastrically. However, 24–48 h after sc injec-
tion, plasma EGCG levels are below the levels of detection.
In contrast, in mice given 0.1% EGCG in their diet, the
plasma EGCG concentration is about 30 ng/ml (66 nM) in
blood samples collected in the light-phase when the mice
were consuming much less EGCG than the average daily
intake. Consequently this EGCG concentration is probably
the minimum level. Nonetheless, the half life of EGCG in
plasma is very short (1.4 h; Lambert et al. 2006). The esti-
mated EGCG concentrations (0.1–1.0 lM) in plasma after
oral or sc administration are sufﬁcient for it to interact with
high afﬁnity targets such as 67LR (Kd = 39.9 nM; Tachi-
bana et al. 2004) and NOX enzyme (IC50 = 3.5 lM; deter-
mined for EGCG as an inhibitor by Steffen et al. 2008), both
of which are over-expressed in dystrophic muscle cells and
tissues (Dorchies et al. 2009;S h k r y le ta l .2009;W h i t e h e a d
etal. 2010). The variations in the amounts of the high afﬁnity
targets in different types of muscles may also affect the
efﬁcacy of EGCG.
The inverse correlation of the EGCG-mediated altera-
tions of locomotor activity with the numbers of LF gran-
ules in diaphragm muscles (Fig. 7b, c) implies that mice
with higher locomotor activities form fewer LF granules in
824 Histochem Cell Biol (2012) 137:811–827
123their muscles. This relationship is independent of routes
and doses of EGCG administration. The diaphragm, which
contracts continuously, may resist the oxidative stress
caused by locomotion more than locomotor muscles, such
as EDL muscle. The correlation for the EDL is dependent
on the routes and doses of EGCG administration: the 0.1%
oral EGCG treatment led to a similar correlation as in the
diaphragm, but 10 mg/kg EGCG injected sc resulted in an
opposite correlation (Fig. 7e, f). This suggests that EDL
muscles in mdx mice given 10 mg/kg EGCG sc, whose
locomotor activities are close to normal levels (Fig. 4b;
Tables 1, 2), require high amounts of EGCG to counteract
the effects of activity-mediated oxidative stress. Nonethe-
less, the formation of slightly more LF granules in EDL
muscles in mdx mice injected sc with 10 mg/kg EGCG is
probably attributable to such stress (Fig. 5 h; Tables 1, 2).
The different resistance of EDL and diaphragm muscles to
oxidative stress may be due to different expression of high
afﬁnity targets for EGCG.
In summary, sc injection of 5 mg/kg EGCG 4 times a
week led, compared to the other two dose–route protocols,
to the highest average reduction in serum CK levels, the
second best improvement in locomotor activity and Pi and
Po, but no signiﬁcant reduction in the amount of LF in
diaphragm muscle. Doubling the sc dose of EGCG resulted
in the greatest increase in locomotor activity. However, this
improvement was accompanied by an insigniﬁcant reduc-
tion in diaphragm LF, an insigniﬁcant increase in EDL LF
and the lowest increases in Pi and Po. Oral administration
of EGCG in the diet produced the greatest reduction in the
amount of LF formed in diaphragm muscle, the greatest
improvement in muscle tensions and hypertrophy, a sig-
niﬁcant reduction in the ﬁbrosis of the EDL muscle and
serum CK levels, but a relatively poor improvement in
locomotor activity. The greater efﬁcacy of the oral route is
probably due to maintaining a plasma concentration of
EGCG of at least 66 nM throughout the treatment period.
We conclude that the efﬁcacy of EGCG found in this
and previous studies for improving the structure and
function of muscles in mdx mice suggests that EGCG may
be of beneﬁt for DMD patients.
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